Jacobio Pharmaceuticals Group Co., Ltd. (01167.HK)

Jacobio Pharmaceuticals Group Co., Ltd. is an investment holding company, which engages in the research and development of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 196 full-time employees. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-21822 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly operates its businesses in China market.